Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS

This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. This episode focuses on updates in myelodysplastic syndromes (MDS). 

You will hear insights into managing anemia in lower-risk MDS (LR-MDS) from Sophie Park, MD, CHU Grenoble Alpes, Grenoble, France, Esther Oliva, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, and Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany. They share data from the EPO-Pretar trial (NCT03223961), which is investigating early versus late onset of epoetin alfa treatment, an analysis of patient-reported outcomes in the COMMANDS trial (NCT03682536), and the effect of prior therapies on the activity of imetelstat in the IMerge trial (NCT02598661).

Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, and Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, then go on to discuss novel approaches to managing higher-risk MDS (HR-MDS), including an individualized allogeneic stem cell transplantation (alloSCT) approach and novel non-transplant treatment approaches.